UBT251 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?

UBT251 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?

Send a text

This episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.

00:00 – Cold Open: Lilly vs Novo Shock Timing
Dave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match.

03:20 – Novo Nordisk Price Cuts Explained
Deep dive into Novo’s plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning.

07:25 – Tirzepatide vs Semaglutide Head to Head Trial
Breakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially.

11:55 – Market Reaction and Strategic Implications
Discussion of stock movement, competitive signaling, and how Novo’s pricing move may blunt Lilly’s trial victory.

14:25 – Novo Triple Agonist Data Drops
Shift into Novo’s early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists.

16:00 – Comparing Novo’s Triple to Retatrutide
Analysis of weight loss percentages versus Lilly’s retatrutide data and the caution required when comparing across trials.

18:15 – The Triple Agonist Era
Broader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term.

20:00 – Clinical Trial Results vs Real World Reality
Reminder that clinical trial outcomes do not automatically translate to everyday patient experience.

22:30 – Data Refresher on Allurion Ballon Approval
Quick recap of the headline numbers and strategic landscape as innovation and pricing

Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

🤝 Visit Our Sponsors!
OTPLinks.com

Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4

MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen

WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv


📲 Contact Me: dave@onthepen.com

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(207)

  We’re Solving Obesity. Now Who Pays for It?

We’re Solving Obesity. Now Who Pays for It?

This week on On The Pen, the GLP-1 story is moving in two very different directions.The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its con...

2 Syys 24min

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health.In this episode of the On The Pen Podcast, Dave Knapp breaks ...

26 Elo 34min

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America.But gett...

18 Elo 45min

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

Https://www.otplinks.comBased on the transcript flow, here’s a clean YouTube description with chapter timestamps. The transcript itself doesn’t include timecodes, so these are estimated from speaking ...

12 Elo 31min

Eli Lilly Earnings Call Recap: Retatrutide News

Eli Lilly Earnings Call Recap: Retatrutide News

https://www.otplinks.com

7 Elo 59min

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes i...

4 Elo 18min

Retatrutide Biologic Battle: The Story Gets Bigger

Retatrutide Biologic Battle: The Story Gets Bigger

https://www.otplinks.comhttps://www.voafit.com/otpEpisode Referenced: https://www.youtube.com/watch?v=K8kaSoFCZ0c&t=41sThe retatrutide biologic fight is bigger than folks understand.This breakdown cov...

28 Heinä 20min

GLP-1 Showdown: Inside The High Stakes War over Patients

GLP-1 Showdown: Inside The High Stakes War over Patients

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode...

22 Heinä 27min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
rss-pitaisko-erota
tiedenaiset-podcast
psykopodiaa-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
terapiassa
meditaatiot-suomeksi
katilon-kahvitunti
rss-kuumilla-aalloilla
rss-uplevel-by-sonja-hannus
rss-pt-paahtio
rss-sanelunpurku-podcast
voi-hyvin-meditaatiot-2
fitnessvastaanotto
selviytyjat-tarinoita-elamasta
rss-terapiaklubi
rss-vapaudu-voimaasi
paritellen
junnut-pelissa
rss-rakas-mielenterveyteni